New Study Illuminates Cancer Risk and Protection in Down Syndrome

A study led by Karolinska Institutet has delved into the lifetime risk of cancer among individuals with Down syndrome, revealing complex insights into cancer susceptibility.

The findings indicate a high risk of leukemia early in life for individuals with Down syndrome. Simultaneously, the study notes that the majority of children with Down syndrome do not develop cancer.

Researchers suggest that trisomy 21, the genetic condition associated with Down syndrome, may offer a protective effect against several types of solid tumors.

This observation presents opportunities for in-depth research into potential cancer-suppressive mechanisms, which could have implications beyond individuals with Down syndrome.

Implications for Screening Guidelines

The results may contribute to more precise and individualized cancer screening guidelines. Such guidelines could involve modifying existing screening procedures, such as breast cancer screening methods, and introducing new ones, like targeted testicular examinations.

The results may contribute to more precise and individualized cancer screening guidelines.

Study Design and Data Sources

The study analyzed data from nearly 10,000 individuals with Down syndrome born in Sweden between 1930 and 2017. Participants were identified by linking information from various national registers, including the National Patient Register, Medical Birth Register, Cancer Register, and the Swedish Childhood Cancer Register.

Each individual with Down syndrome was matched with 50 control subjects of the same sex, birth year, and county, and their incidence of different cancer types was monitored over time.

Next Steps and Research Focus

Future work includes developing consensus cancer screening guidelines tailored for individuals with Down syndrome. Further biological studies are also planned to confirm and understand the mechanisms by which chromosome 21 may protect against solid tumors.

Funding Support

The study received funding from organizations such as the Swedish Childhood Cancer Fund, the Swedish Research Council, and the Swedish Cancer Society.